STOCK TITAN

AVROBIO, Inc. - AVRO STOCK NEWS

Welcome to our dedicated page for AVROBIO news (Ticker: AVRO), a resource for investors and traders seeking the latest updates and insights on AVROBIO stock.

AVROBIO, Inc. (symbol: AVRO) is a pioneering clinical-stage gene therapy company dedicated to transforming the lives of patients with cancer and rare genetic diseases. The company focuses on developing potentially curative ex vivo lentiviral gene therapies, offering hope for long-term, potentially lifelong benefits from a single-dose treatment regimen.

AVROBIO's innovative pipeline includes several promising product candidates:

  • AVR-RD-04: Designed for the treatment of cystinosis, a rare metabolic disorder that can lead to kidney and eye complications.
  • AVR-RD-02: Targeting Gaucher disease type 1, which affects the spleen, liver, and bone marrow, this therapy aims to significantly improve patients' quality of life.
  • AVR-RD-05: Developed to combat Hunter syndrome (MPS II), a disorder impacting cognitive development and physical health.
  • AVR-RD-03: Intended for the treatment of Pompe disease, a condition that leads to progressive muscle weakness and respiratory failure.

AVROBIO is committed to advancing its clinical programs and leveraging strategic partnerships to enhance the development and commercialization of its therapies. The company continually updates the market with the latest progress and achievements through press releases and collaborations with other industry leaders.

The latest news from AVROBIO includes significant updates on clinical trials, technological advancements, and strategic partnerships. For instance, new collaborations with Tectonic Therapeutic, Inc. underscore AVROBIO's commitment to innovation and expanding its therapeutic reach. Financially, AVROBIO remains focused on maintaining a solid financial foundation to support its ambitious research and development activities.

With a mission to deliver transformative therapies to patients with unmet medical needs, AVROBIO is at the forefront of the gene therapy revolution, continually pushing the boundaries of what is possible in the treatment of rare diseases.

Rhea-AI Summary

AVROBIO, Inc. (Nasdaq: AVRO) announced the granting of a non-statutory stock option for up to 8,250 shares of its common stock to a new employee. This inducement award aligns with Nasdaq Listing Rule 5635(c)(4). The stock option, granted on June 1, 2021, has an exercise price of $9.13 per share, matching AVROBIO's closing stock price on the grant date. It features a 10-year term with a four-year vesting schedule. AVROBIO is focused on advancing its gene therapy programs targeting genetic diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
none
-
Rhea-AI Summary

AVROBIO, a clinical-stage gene therapy company, reported a net loss of $26.9 million for Q1 2021, slightly higher than the $26 million loss in Q1 2020. R&D expenses rose to $18.5 million, driven by increased program activities and personnel costs. The company engaged with the FDA regarding AVR-RD-01 for Fabry disease and plans to seek feedback for a registration trial in late 2021. Recent data presented at the WORLDSymposium™ showed promising outcomes across Fabry, Gaucher, and cystinosis trials. AVROBIO holds $233 million in cash, projected to sustain operations into Q1 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

AVROBIO, a clinical-stage gene therapy company, announced the granting of non-statutory stock options for 163,500 shares to five new employees as inducement awards. The options, approved by the Compensation Committee, include 30,500 shares from the 2019 Inducement Plan and 133,000 from the 2020 Inducement Plan, with an exercise price of $9.48 per share as of May 3, 2021. The vesting schedule spans 10 years, with 25% on the first anniversary and the remainder monthly over three years, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
Rhea-AI Summary

AVROBIO, Inc. (Nasdaq: AVRO) announced a strategic update regarding its investigational gene therapy AVR-RD-01 for Fabry disease. Following a recent FDA approval of Fabrazyme®, AVROBIO intends to shift from an accelerated approval pathway to a registration trial. The company plans to use kidney biopsy as a primary efficacy endpoint. AVROBIO is also modifying its ongoing FAB-GT trial to include more diverse participants. CEO Geoff MacKay expressed commitment to quicken the approval process to benefit those affected by Fabry disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.84%
Tags
none
-
Rhea-AI Summary

AVROBIO, Inc. (Nasdaq: AVRO) announced presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy, scheduled for May 11-14, 2021. New data from a Phase 1/2 trial in cystinosis and preclinical findings in Pompe disease will be highlighted. Presentations include oral discussions on AVR-RD-03 for Pompe disease and AVR-RD-01 for Fabry disease, along with poster sessions on ongoing clinical trials for cystinosis and Gaucher disease type 1. The meeting underscores the company’s commitment to advancing gene therapy for lysosomal disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences clinical trial
-
Rhea-AI Summary

AVROBIO (Nasdaq: AVRO) announced the granting of non-statutory stock options for up to 140,000 shares to 10 new employees as part of its 2019 Inducement Plan. These options were approved by the Compensation Committee and were granted on April 1, 2021, with an exercise price of $12.31 per share. The options vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments. AVROBIO aims to provide personalized gene therapy to combat genetic diseases, and its pipeline includes treatments for various conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
none
Rhea-AI Summary

AVROBIO, Inc. (Nasdaq: AVRO) announced its financial results for Q4 and the year ending December 31, 2020, reporting a net loss of $28.1 million for Q4 and $119.7 million for the year, attributed to increased R&D and administrative expenses. The company highlighted significant advancements in its gene therapy pipeline, including a 100% reduction in toxic substrate in the FAB-GT trial for Fabry disease. AVROBIO expects to achieve operational milestones, including discussions with the FDA regarding AVR-RD-01's regulatory path, and anticipates funding its operations into Q1 2023 with $259.7 million in cash.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.64%
Tags
-
Rhea-AI Summary

AVROBIO, Inc. (Nasdaq: AVRO) has granted non-statutory stock options for 61,500 shares of common stock to five new employees as inducement awards under its 2019 Inducement Plan. The stock options, with an exercise price of $11.45 per share, were approved by the Compensation Committee and granted on March 1, 2021. The options have a 10-year term and vest over four years, subject to continued employment. AVROBIO focuses on personalized gene therapy, aiming to treat genetic diseases through its ex vivo lentiviral gene therapy pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.4%
Tags
none
-
Rhea-AI Summary

AVROBIO, Inc (Nasdaq: AVRO) announces that the European Commission has granted orphan drug designation for its investigational gene therapy AVR-RD-04 aimed at treating cystinosis. This gene therapy utilizes the patient's own modified stem cells to produce cystinosin, addressing the protein deficiency caused by cystinosis. Currently evaluated in a Phase 1/2 clinical trial, AVR-RD-04 has also received U.S. orphan drug status. This designation offers benefits like reduced fees and potential market exclusivity, underscoring its therapeutic promise in a challenging treatment landscape.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
none
Rhea-AI Summary

AVROBIO, Inc. (Nasdaq: AVRO), a clinical-stage gene therapy company, announced that its senior management will participate in three virtual investor conferences:

  • Cowen 41st Annual Health Care Conference - March 4, 2021, at 10:30 a.m. ET
  • Barclays Global Healthcare Conference - March 9, 2021, at 8:35 a.m. ET
  • Morgan Stanley Virtual Healthcare Corporate Access Day - March 16, 2021

Live webcasts will be available on avrobio.com, and the Barclays event will be archived for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
conferences

FAQ

What is the current stock price of AVROBIO (AVRO)?

The current stock price of AVROBIO (AVRO) is $1.4 as of June 20, 2024.

What is the market cap of AVROBIO (AVRO)?

The market cap of AVROBIO (AVRO) is approximately 62.9M.

What does AVROBIO, Inc. specialize in?

AVROBIO, Inc. specializes in developing ex vivo lentiviral gene therapies aimed at treating rare diseases and cancers through a single-dose treatment regimen.

What are the key products in AVROBIO's pipeline?

The key products in AVROBIO's pipeline include AVR-RD-04 for cystinosis, AVR-RD-02 for Gaucher disease type 1, AVR-RD-05 for Hunter syndrome, and AVR-RD-03 for Pompe disease.

How does AVROBIO's gene therapy work?

AVROBIO's gene therapy involves ex vivo lentiviral gene editing, which means modifying the patient's cells outside their body and then reintroducing them to treat the underlying cause of the disease.

What recent achievements has AVROBIO announced?

Recent achievements include advancements in clinical trials, new strategic partnerships, and collaborations with companies like Tectonic Therapeutic, Inc.

What is the financial condition of AVROBIO?

AVROBIO is focused on maintaining a strong financial foundation to support its research and development efforts, though it is important to check the latest financial reports for current details.

Who are AVROBIO's partners in their gene therapy development?

AVROBIO collaborates with various industry leaders, including Tectonic Therapeutic, Inc., to enhance its gene therapy development and commercialization efforts.

What is the significance of AVROBIO's work on rare diseases?

AVROBIO's work is significant because it offers potentially curative treatments for rare diseases, which often have limited or no effective treatment options available.

What is ex vivo lentiviral gene therapy?

Ex vivo lentiviral gene therapy is a technique where cells are modified outside the patient's body using lentiviral vectors and then reintroduced to correct or mitigate genetic disorders.

How does AVROBIO intend to deliver their therapies to patients?

AVROBIO aims to deliver their therapies through a single-dose treatment regimen, which could provide long-term benefits and potentially lifelong improvement in quality of life.

Where can I find the latest news about AVROBIO?

The latest news about AVROBIO can be found on their official website, press releases, and financial news websites like StockTitan, among others.

AVROBIO, Inc.

Nasdaq:AVRO

AVRO Rankings

AVRO Stock Data

62.85M
44.89M
0.4%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE